Unknown

Dataset Information

0

Efficacy and Safety of Sugammadex to Shorten Time-to-Extubation Following Cardiac Surgery: A Single-Center Randomized Placebo-Controlled Trial.


ABSTRACT: Residual neuromuscular blockade (NMB) is an important and modifiable factor associated with prolonged mechanical ventilation after cardiac surgery. Studies evaluating the use of sugammadex for residual NMB reversal in the post-cardiac surgery ICU setting are lacking. We conducted a randomized trial to determine the efficacy of sugammadex in reducing time to extubation in patients admitted to the ICU after cardiac surgery.

Design

Single-center, randomized, double-blind, placebo-controlled trial.

Setting

University-based cardiothoracic ICU.

Subjects

Patients (n = 90) undergoing elective aortic valve replacement (AVR) and/or coronary artery bypass grafting (CABG) surgery.

Interventions

Participants were randomized to receive either sugammadex (2 mg/kg) or placebo after arrival to the ICU.

Measurements and main results

The primary study endpoint was time from study drug administration to extubation. Of the 90 patients included in the study (45 in each group), a total of 68 patients underwent CABG, 13 AVR, and nine combined AVR and CABG. Baseline characteristics and intraoperative anesthetic medications were comparable between groups. Patients in sugammadex group had reduced time to extubation compared with the placebo group (median [interquartile range (IQR)]-sugammadex group: 126.0 min [84.0-274.0 min] vs placebo: 219.0 min [121.0-323.0 min]; difference in means [95% CI], 72.8 [1.5-144.1 min]; p = 0.01. There were no differences in negative inspiratory force (mean [sd]-sugammadex group: 33.79 cm H2O [8.39 cm H2O] vs placebo: -31.11 cm H2O [7.17 cm H2O]) and vital capacity (median [IQR]-sugammadex group: 1.1 L [0.9-1.3 L] vs placebo: 1.0 L [0.9-1.2 L]). There were no differences between groups in postoperative blood product requirement, dysrhythmias, length of ICU, or hospital stay. There were no serious adverse events in either group.

Conclusions

This randomized trial showed that the administration of sugammadex after cardiac surgery decreased time to extubation by approximately 1 hour. Larger trials may be required to confirm these findings and determine the clinical implications.

SUBMITTER: Bardia A 

PROVIDER: S-EPMC9788969 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy and Safety of Sugammadex to Shorten Time-to-Extubation Following Cardiac Surgery: A Single-Center Randomized Placebo-Controlled Trial.

Bardia Amit A   Treggiari Miriam M MM   Dai Feng F   Johnson Chanel C   Singh Manila M   Kunze Kim K   Tickoo Mayanka M   Tantawy Hossam H   Giersson Arnar A   Darr Umer U   Schonberger Robert B RB  

Critical care explorations 20221222 12


Residual neuromuscular blockade (NMB) is an important and modifiable factor associated with prolonged mechanical ventilation after cardiac surgery. Studies evaluating the use of sugammadex for residual NMB reversal in the post-cardiac surgery ICU setting are lacking. We conducted a randomized trial to determine the efficacy of sugammadex in reducing time to extubation in patients admitted to the ICU after cardiac surgery.<h4>Design</h4>Single-center, randomized, double-blind, placebo-controlled  ...[more]

Similar Datasets

| S-EPMC11895371 | biostudies-literature
| S-EPMC7541477 | biostudies-literature
| S-EPMC9058191 | biostudies-literature
| S-EPMC6893217 | biostudies-literature
| S-EPMC9576842 | biostudies-literature
| S-EPMC6431279 | biostudies-literature
| S-EPMC9267492 | biostudies-literature
| S-EPMC4425500 | biostudies-literature
| S-EPMC6352235 | biostudies-literature
| S-EPMC11921262 | biostudies-literature